Vorinostat is a member of a larger class of compounds that inhibit histone deacetylases (HDAC) and it is used to treat cutaneous T cell lymphoma (CTCL). Here, HDAC9 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.